Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease
Launched by PABLO JUAN-SALVADORES · Jun 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how air quality affects the development and worsening of coronary artery disease (CAD) in young people. Researchers want to understand how environmental pollution impacts heart health, particularly for those under 40 who have been diagnosed with CAD. By looking at information from patients in Galicia, the study aims to identify patterns and differences based on gender, which could help improve treatment and prevention strategies for young patients.
To participate, individuals must be between 18 and 40 years old. Those with a diagnosis of CAD, such as heart attacks or angina, are considered "cases." People without any history of CAD or other related heart conditions will be part of the "control" group. Participants can expect to provide information about their health and living conditions, which will help researchers gather important data on the relationship between air pollution and heart disease. This study is currently recruiting, and participants will contribute to valuable research that may lead to better health outcomes for young people facing heart issues.
Gender
ALL
Eligibility criteria
- CASES:
- Inclusion Criteria:
- • Women and men between 18 and 40 years old with a diagnosis of coronary artery disease coded in their medical records in Galicia
- Exclusion Criteria:
- • Not having a postal code and primary care center assigned in their medical records in Galicia
- • CONTROL
- Inclusion Criteria:
- • Women and men between 18 and 40 years old with no diagnosis or history of CAD or other coronary disease coded in their medical records
- Exclusion Criteria:
- • Present with non-ischemic coronary diseas.
- • Have a serious condition that affects or decreases life expectancy.
- • Do not have a postal code or primary care center assigned in their medical records in Galicia
About Pablo Juan Salvadores
Pablo Juan-Salvadores is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With expertise in designing and managing innovative clinical studies, he focuses on developing novel therapeutic solutions across various therapeutic areas. His approach emphasizes collaboration with healthcare professionals, regulatory bodies, and research institutions to ensure the highest standards of safety, efficacy, and compliance. Through rigorous methodologies and a patient-centered perspective, Pablo Juan-Salvadores aims to contribute to the scientific community and enhance the quality of care in clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vigo, Pontevedra, Spain
Patients applied
Trial Officials
Pablo Juan-Salvadores, Pharma, PhD
Principal Investigator
Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported